Comparative Outcomes of Preoperative and Postoperative Stereotactic Radiosurgery in Patients Undergoing Resection for Brain Metastases: Systematic Review and Meta-Analysis
Volume 2, Issue 2, Winter 2026, Pages 137-146
https://doi.org/10.22034/mphrj.2026.576870.1080
Ali Mohamadi Moghadam
Abstract Brain metastases represent the most common intracranial tumors in adults, frequently requiring multimodal management including surgical resection and stereotactic radiosurgery (SRS). The optimal timing of SRS—either administered preoperatively or postoperatively— remains a subject of ongoing debate. This systematic review and meta-analysis aimed to compare clinical outcomes between preoperative and postoperative SRS in patients undergoing surgical resection for brain metastases. A comprehensive literature search conducted across major databases including PubMed, Scopus, and Web of Science up to 2025. Studies directly comparing preoperative and postoperative SRS in adult patients with resectable brain metastases were included. Primary outcomes were local control, leptomeningeal disease (LMD) incidence, radiation necrosis, overall survival (OS), and distant brain failure (DBF). Data were pooled using random-effects models, and heterogeneity assessed using the I² statistic. Across eligible retrospective and prospective cohort studies, preoperative SRS demonstrated significantly lower rates of LMD and symptomatic radiation necrosis compared with postoperative SRS. Local control rates were comparable between groups, while overall survival did not differ significantly. Preoperative SRS was associated with improved target delineation and reduced irradiation volume, potentially explaining the lower complication rates. In conclusion, preoperative SRS appears to provide similar oncologic control with reduced treatment-related toxicity compared to postoperative SRS. These findings support consideration of preoperative SRS as an effective alternative strategy in appropriately selected patients, although randomized controlled trials are required to confirm long-term comparative benefits.


